Compared with previous trials, the prospective use of KL-6 as an entry requirement is a unique feature of this trial, which is supported by retrospective analysis of previous studies that showed KL-6 as a predictive marker of progressive lung disease.33,47,48. This evidence concerns the gene MUC1 and lung disorder.